At CLONOVA, we are at the forefront of developing biosimilar monoclonal antibodies (mAbs) using cutting-edge genetic engineering tools and innovative bioprocess technologies across both upstream and downstream platforms. Our goal is to deliver high-quality, affordable biologics that meet rigorous global standards of safety, efficacy, and consistency.
Biosimilars play a crucial role in enhancing patient access to life-saving therapies while reducing the overall cost of healthcare, particularly in the treatment of oncological, autoimmune, and other complex chronic diseases.
With a strong commitment to innovation and quality, CLONOVA is building a robust pipeline of monoclonal antibodies designed for global reach. Our flexible partnering model enables strategic collaborations with international pharmaceutical companies, healthcare providers, and research institutions — ensuring faster development, efficient commercialization, and broader patient impact worldwide.
Pembrolizumab (Biosimilar)
Indication: Oncology / Immuno-oncology
Pembrolizumab is a humanized monoclonal antibody targeting the PD-1 receptor, designed to restore the body’s immune response against cancer cells. It is indicated for the treatment of various advanced cancers, including melanoma, non-small cell lung cancer, and head and neck squamous cell carcinoma.
Denosumab (Biosimilar)
Indication: Bone Disorders / Oncology Supportive Care Denosumab is a monoclonal antibody that inhibits RANKL, a key factor in bone resorption. It is
indicated for the treatment of osteoporosis and for preventing skeletal-related events in patients with bone metastases from solid tumors.
Secukinumab (Biosimilar)
Indication: Immunology / Autoimmune Diseases Secukinumab is an IL-17A inhibitor used in the management of chronic inflammatory conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by targeting the inflammatory pathways responsible for these autoimmune diseases.
Dupilumab (Biosimilar)
Indication: Immunology / Dermatology & Respiratory Dupilumab is a monoclonal antibody that blocks IL-4 and IL-13 signaling, key drivers of type 2 inflammation. It is indicated for moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.
